Medprin Regenerative Medical Technologies Co.,Ltd. (301033.SZ) announced that its self-developed dural sealant product has recently been accepted by the Center for Medical Device Evaluation of the National Medical Products Administration to enter the special review program for innovative medical devices. The dural sealant is indicated for assisting in the closure of dural suture sites to prevent cerebrospinal fluid leakage. Based on an electrophile-nucleophile reaction mechanism, the product utilizes a globally leading patented technical formula and auxiliary accessories to achieve immediate and efficient sealing of dural suture sites during surgical procedures.